IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-41537-7.html
   My bibliography  Save this article

mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States

Author

Listed:
  • Hung Fu Tseng

    (Kaiser Permanente Southern California
    Kaiser Permanente Bernard J. Tyson School of Medicine)

  • Bradley K. Ackerson

    (Kaiser Permanente Southern California)

  • Lina S. Sy

    (Kaiser Permanente Southern California)

  • Julia E. Tubert

    (Kaiser Permanente Southern California)

  • Yi Luo

    (Kaiser Permanente Southern California)

  • Sijia Qiu

    (Kaiser Permanente Southern California)

  • Gina S. Lee

    (Kaiser Permanente Southern California)

  • Katia J. Bruxvoort

    (Kaiser Permanente Southern California
    University of Alabama at Birmingham)

  • Jennifer H. Ku

    (Kaiser Permanente Southern California)

  • Ana Florea

    (Kaiser Permanente Southern California)

  • Harpreet S. Takhar

    (Kaiser Permanente Southern California)

  • Radha Bathala

    (Kaiser Permanente Southern California)

  • Cindy Ke Zhou

    (Moderna Inc.)

  • Daina B. Esposito

    (Moderna Inc.)

  • Morgan A. Marks

    (Moderna Inc.)

  • Evan J. Anderson

    (Moderna Inc.)

  • Carla A. Talarico

    (Moderna Inc.
    AstraZeneca)

  • Lei Qian

    (Kaiser Permanente Southern California)

Abstract

The bivalent (original and Omicron BA.4/BA.5) mRNA-1273 COVID-19 vaccine was authorized to offer broader protection against COVID-19. We conducted a matched cohort study to evaluate the effectiveness of the bivalent vaccine in preventing hospitalization for COVID-19 (primary outcome) and medically attended SARS-CoV-2 infection and hospital death (secondary outcomes). Compared to individuals who did not receive bivalent mRNA vaccination but received ≥2 doses of any monovalent mRNA vaccine, the relative vaccine effectiveness (rVE) against hospitalization for COVID-19 was 70.3% (95% confidence interval, 64.0%–75.4%). rVE was consistent across subgroups and not modified by time since last monovalent dose or number of monovalent doses received. Protection was durable ≥3 months after the bivalent booster. rVE against SARS-CoV-2 infection requiring emergency department/urgent care and against COVID-19 hospital death was 55.0% (50.8%–58.8%) and 82.7% (63.7%–91.7%), respectively. The mRNA-1273 bivalent booster provides additional protection against hospitalization for COVID-19, medically attended SARS-CoV-2 infection, and COVID-19 hospital death.

Suggested Citation

  • Hung Fu Tseng & Bradley K. Ackerson & Lina S. Sy & Julia E. Tubert & Yi Luo & Sijia Qiu & Gina S. Lee & Katia J. Bruxvoort & Jennifer H. Ku & Ana Florea & Harpreet S. Takhar & Radha Bathala & Cindy Ke, 2023. "mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-41537-7
    DOI: 10.1038/s41467-023-41537-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-41537-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-023-41537-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Julia Stowe & Nick Andrews & Freja Kirsebom & Mary Ramsay & Jamie Lopez Bernal, 2022. "Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    2. Roanne Keeton & Marius B. Tincho & Amkele Ngomti & Richard Baguma & Ntombi Benede & Akiko Suzuki & Khadija Khan & Sandile Cele & Mallory Bernstein & Farina Karim & Sharon V. Madzorera & Thandeka Moyo-, 2022. "T cell responses to SARS-CoV-2 spike cross-recognize Omicron," Nature, Nature, vol. 603(7901), pages 488-492, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Denis Mongin & Nils Bürgisser & Gustavo Laurie & Guillaume Schimmel & Diem-Lan Vu & Stephane Cullati & Delphine Sophie Courvoisier, 2023. "Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    2. Jaime S. Rosa Duque & Xiwei Wang & Daniel Leung & Samuel M. S. Cheng & Carolyn A. Cohen & Xiaofeng Mu & Asmaa Hachim & Yanmei Zhang & Sau Man Chan & Sara Chaothai & Kelvin K. H. Kwan & Karl C. K. Chan, 2022. "Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    3. Daniel Mrak & Daniela Sieghart & Elisabeth Simader & Selma Tobudic & Helga Radner & Peter Mandl & Lisa Göschl & Maximilian Koblischke & Nikolaus Hommer & Angelika Wagner & Margareta Mayer & Lorenz Sch, 2022. "Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    4. Zhuoying Huang & Shuangfei Xu & Jiechen Liu & Linlin Wu & Jing Qiu & Nan Wang & Jia Ren & Zhi Li & Xiang Guo & Fangfang Tao & Jian Chen & Donglei Lu & Yuheng Wang & Juan Li & Xiaodong Sun & Weibing Wa, 2023. "Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    5. Laurent Renia & Yun Shan Goh & Angeline Rouers & Nina Bert & Wan Ni Chia & Jean-Marc Chavatte & Siew‐Wai Fong & Zi Wei Chang & Nicole Ziyi Zhuo & Matthew Zirui Tay & Yi-Hao Chan & Chee Wah Tan & Nicho, 2022. "Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    6. Hung Fu Tseng & Bradley K. Ackerson & Katia J. Bruxvoort & Lina S. Sy & Julia E. Tubert & Gina S. Lee & Jennifer H. Ku & Ana Florea & Yi Luo & Sijia Qiu & Soon Kyu Choi & Harpreet S. Takhar & Michael , 2023. "Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    7. Annika Rössler & Antonia Netzl & Ludwig Knabl & Helena Schäfer & Samuel H. Wilks & David Bante & Barbara Falkensammer & Wegene Borena & Dorothee Laer & Derek J. Smith & Janine Kimpel, 2022. "BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    8. Matthias Reinscheid & Hendrik Luxenburger & Vivien Karl & Anne Graeser & Sebastian Giese & Kevin Ciminski & David B. Reeg & Valerie Oberhardt & Natascha Roehlen & Julia Lang-Meli & Kathrin Heim & Nina, 2022. "COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    9. Daan K. J. Pieren & Sebastián G. Kuguel & Joel Rosado & Alba G. Robles & Joan Rey-Cano & Cristina Mancebo & Juliana Esperalba & Vicenç Falcó & María J. Buzón & Meritxell Genescà, 2023. "Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    10. Julia T. Castro & Patrick Azevedo & Marcílio J. Fumagalli & Natalia S. Hojo-Souza & Natalia Salazar & Gregório G. Almeida & Livia I. Oliveira & Lídia Faustino & Lis R. Antonelli & Tomas G. Marçal & Ma, 2022. "Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    11. Georg M. N. Behrens & Joana Barros-Martins & Anne Cossmann & Gema Morillas Ramos & Metodi V. Stankov & Ivan Odak & Alexandra Dopfer-Jablonka & Laura Hetzel & Miriam Köhler & Gwendolyn Patzer & Christo, 2022. "BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    12. Lloyd A. C. Chapman & Maite Aubry & Noémie Maset & Timothy W. Russell & Edward S. Knock & John A. Lees & Henri-Pierre Mallet & Van-Mai Cao-Lormeau & Adam J. Kucharski, 2023. "Impact of vaccinations, boosters and lockdowns on COVID-19 waves in French Polynesia," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    13. Freja Cordelia Møller Kirsebom & Nick Andrews & Ruchira Sachdeva & Julia Stowe & Mary Ramsay & Jamie Lopez Bernal, 2022. "Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    14. Hassen Kared & Asia-Sophia Wolf & Amin Alirezaylavasani & Anthony Ravussin & Guri Solum & Trung The Tran & Fridtjof Lund-Johansen & John Torgils Vaage & Lise Sofie Nissen-Meyer & Unni C. Nygaard & Ola, 2022. "Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    15. Fanglei Zuo & Hassan Abolhassani & Likun Du & Antonio Piralla & Federico Bertoglio & Leire Campos-Mata & Hui Wan & Maren Schubert & Irene Cassaniti & Yating Wang & Josè Camilla Sammartino & Rui Sun & , 2022. "Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    16. Chihiro Motozono & Mako Toyoda & Toong Seng Tan & Hiroshi Hamana & Yoshihiko Goto & Yoshiki Aritsu & Yusuke Miyashita & Hiroyuki Oshiumi & Kimitoshi Nakamura & Seiji Okada & Keiko Udaka & Mizuki Kitam, 2022. "The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    17. Yuexiu Zhang & Michelle Chamblee & Jiayu Xu & Panke Qu & Mohamed M. Shamseldin & Sung J. Yoo & Jack Misny & Ilada Thongpan & Mahesh KC & Jesse M. Hall & Yash A. Gupta & John P. Evans & Mijia Lu & Chen, 2024. "Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    18. Shaofeng Deng & Ying Liu & Rachel Chun-Yee Tam & Pin Chen & Anna Jinxia Zhang & Bobo Wing-Yee Mok & Teng Long & Anja Kukic & Runhong Zhou & Haoran Xu & Wenjun Song & Jasper Fuk-Woo Chan & Kelvin Kai-W, 2023. "An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    19. Lindsey R. Baden & Hana M. El Sahly & Brandon Essink & Dean Follmann & Gregory Hachigian & Cynthia Strout & J. Scott Overcash & Susanne Doblecki-Lewis & Jennifer A. Whitaker & Evan J. Anderson & Kathl, 2024. "Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    20. Khadija Khan & Gila Lustig & Cornelius Römer & Kajal Reedoy & Zesuliwe Jule & Farina Karim & Yashica Ganga & Mallory Bernstein & Zainab Baig & Laurelle Jackson & Boitshoko Mahlangu & Anele Mnguni & Ay, 2023. "Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant," Nature Communications, Nature, vol. 14(1), pages 1-9, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-41537-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.